| Market Cap | 247.45M | P/E | - | EPS this Y | 4.40% | Ern Qtrly Grth | - |
| Income | -52.98M | Forward P/E | -4.46 | EPS next Y | 1.20% | 50D Avg Chg | -20.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 79.00% |
| Dividend | N/A | Price/Book | 2.15 | EPS next 5Y | - | 52W High Chg | -41.00% |
| Recommedations | 2.00 | Quick Ratio | 8.56 | Shares Outstanding | 31.34M | 52W Low Chg | 1,193.00% |
| Insider Own | 10.52% | ROA | -27.81% | Shares Float | 17.95M | Beta | 2.57 |
| Inst Own | 74.84% | ROE | -47.62% | Shares Shorted/Prior | 3.48M/3.39M | Price | 7.63 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 602,894 | Target Price | 14.17 |
| Oper. Margin | - | Earnings Date | May 10 | Volume | 62,103 | Change | 1.87% |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Chardan Capital | Buy | Mar 22, 23 |
| Mizuho | Buy | Mar 17, 23 |
| HC Wainwright & Co. | Buy | Mar 17, 23 |
| HC Wainwright & Co. | Buy | Feb 17, 23 |
| Morgan Stanley | Overweight | Jan 27, 23 |
| Wells Fargo | Overweight | Jan 3, 23 |
| Chardan Capital | Buy | Nov 11, 22 |
| Wells Fargo | Overweight | Sep 14, 22 |
| Morgan Stanley | Equal-Weight | Aug 30, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nichtberger Steven | President & CEO President & CEO | Oct 19 | Buy | 1.2492 | 8,127 | 10,152 | 986,483 | 10/19/22 |
| Bollard Catherine | Director Director | Oct 18 | Buy | 0.9935 | 1,000 | 994 | 1,000 | 10/18/22 |
| Marda Anup | Chief Financial Offi.. Chief Financial Officer | Oct 18 | Buy | 0.9924 | 50,000 | 49,620 | 50,000 | 10/18/22 |
| Simon Mark | Director Director | Oct 18 | Buy | 0.98 | 125,000 | 122,500 | 7,000 | 10/18/22 |
| Binder Gwendolyn | See Remarks See Remarks | Oct 18 | Buy | 0.9947 | 20,000 | 19,894 | 20,000 | 10/18/22 |
| Nichtberger Steven | President & CEO President & CEO | Oct 18 | Buy | 0.9939 | 141,873 | 141,008 | 978,356 | 10/18/22 |